Streamlining Aetna Prior Authorization for Genetic Testing Services

Klivira automates Aetna prior authorization for genetic testing, integrating directly with your EMR to manage complex submissions and accelerate approvals for critical genomic services.

Genetic testing prior authorizations present unique challenges due to evolving clinical guidelines, frequent updates to medical necessity criteria, and the involvement of specialized review entities. For Aetna plans, understanding the specific submission pathways and policy nuances is critical for revenue cycle efficiency and timely patient care.

Navigating Aetna's Prior Authorization Landscape for Genetic Testing

Aetna frequently routes genetic testing prior authorizations through specialized utilization management entities such as eviCore and Avalon Healthcare Services. This adds a layer of complexity, requiring providers to understand not only Aetna's Clinical Policy Bulletins (CPBs) but also the specific clinical criteria and submission portals of these delegated review organizations. Efficiently managing these diverse requirements is essential to avoid delays.

Key Genetic Testing Categories Requiring Aetna Prior Authorization

Hereditary cancer panels (e.g., BRCA1/2, Lynch Syndrome)
Prenatal genetic testing (e.g., non-invasive prenatal screening, carrier screening)
Pharmacogenomics (PGx) testing
Advanced diagnostic laboratory tests
Genetic counseling services when billed separately
Whole exome sequencing and whole genome sequencing

Aetna's Policy Framework and Submission Channels

Aetna's medical necessity criteria for genetic testing are detailed in its publicly available Clinical Policy Bulletins (CPBs). For medical benefit genetic testing, Aetna primarily utilizes the Availity provider portal for prior authorization submissions, alongside supporting X12 278 transactions via clearinghouses. Pharmacy benefit genetic tests, such as certain pharmacogenomic panels, route through CVS Caremark's ePA partners, CoverMyMeds or Surescripts.

Turnaround Times and Compliance Considerations

Prior authorization turnaround times for Aetna genetic testing are governed by state-mandated minimums for commercial plans and by CMS-0057-F requirements for Medicare Advantage and Medicaid managed-care lines of business. Klivira's platform monitors these varying timeframes, ensuring submissions align with payer-published service-level targets and regulatory compliance, including the phased implementation of electronic PA APIs by 2027.

Common Denial Patterns and Appeal Pathways

Denials for Aetna genetic testing often stem from insufficient documentation, lack of medical necessity per CPB criteria, or failure to meet step therapy requirements detailed within specific CPBs. Klivira helps identify common Claim Adjustment Reason Codes (CARC) and Remittance Advice Remark Codes (RARC) for genetic testing, supporting efficient reconsideration, peer-to-peer review, and formal appeal processes documented in Aetna's provider manual.

Klivira's Solution for Genetic Testing PA with Aetna

Klivira’s automation platform integrates directly with your EMR, streamlining the submission of Aetna prior authorizations for genetic testing. By leveraging intelligent routing to Availity, X12 278, or ePA partners, and pre-populating requests with clinical data, we reduce manual effort and accelerate decision times. This enables your team to focus on patient care rather than administrative burdens, improving both efficiency and financial outcomes.

Frequently asked questions

How does Aetna manage prior authorizations for genetic testing through RBMs like eviCore or Avalon?

Aetna frequently delegates genetic testing prior authorization reviews to RBMs such as eviCore and Avalon Healthcare Services. Providers must adhere to the specific clinical criteria and submission guidelines of these entities, in addition to Aetna's overarching Clinical Policy Bulletins. Klivira integrates with these diverse pathways to streamline the submission process.

Where can I find Aetna's medical necessity criteria for genetic testing?

Aetna publishes its medical necessity criteria for genetic testing in its Clinical Policy Bulletins (CPBs), which are publicly accessible in the Aetna CPB library. It is crucial to reference the specific CPB number and review date relevant to the genetic test in question, as these policies are regularly updated.

Which submission channels does Aetna support for genetic testing prior authorizations?

For medical benefit genetic testing, Aetna primarily uses the Availity provider portal and supports X12 278 transactions. Pharmacy benefit genetic tests are routed through CVS Caremark's ePA partners, CoverMyMeds or Surescripts. Klivira's platform connects to all these channels, automating the appropriate submission based on the benefit category.

What are common reasons for Aetna to deny genetic testing prior authorizations?

Common denial reasons for Aetna genetic testing include insufficient clinical documentation to support medical necessity, failure to meet specific criteria outlined in the relevant Clinical Policy Bulletin, or not adhering to required step therapy protocols. Understanding the specific CARC and RARC codes can help in preparing effective appeals.

Does CMS-0057-F impact Aetna genetic testing prior authorizations?

Yes, for Aetna's Medicare Advantage, Medicaid managed-care (Aetna Better Health), and CHIP managed-care lines of business, CMS-0057-F introduces new requirements for prior authorization decision timeframes (72 hours for standard, 24 hours for expedited) and electronic PA API conformance by 2027. This rule directly impacts the processing of genetic testing PAs for these specific plans.